## Edgar Filing: BIENAIME JEAN JACQUES - Form 4

BIENAIME Form 4 November ( FORN	ЛЛ		SECUI	RITIES 2	AND EX	(CH4	ANGE CO	OMMISSION	OMB AF	PROVAL	
Check th if no lon subject t Section Form 4 c	his box	Washington, D.C. 20549 x STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES									
	to <b>SIAIEN</b> 16.										
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations may continue. See Instruction 1(c) Form 5 Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 (C) (C) (C) (C) (C) (C) (C) (C)											
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> BIENAIME JEAN JACQUES								5. Relationship of Reporting Person(s) to Issuer			
		INC [BMRN]					(Check all applicable)				
(Last) C/O BIOM PHARMA DIGITAL	(Month/Dav/Year)					_X_ Director 10% Owner _X_ Officer (give title Other (specify below) below) Chief Executive Officer					
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)					<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>						
Person											
(City)	(State)	(Zip)					_	<b>ired, Disposed of,</b> 5. Amount of			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	ution Date, if Transactionor Disposed Code (Instr. 3, 4 hth/Day/Year) (Instr. 8)				d of (D) and 5) Securities Beneficially Owned Following Reported Transaction(s) or (Instr. 3 and 4		o. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	11/07/2012	11/07/20	)12	Code V S	Amount 2,000	(D) D	Price \$ 47.7304 (1)	172,691	D		
Common Stock	11/07/2012	11/07/20	012	S	3,000	D	\$ 47.003 (2)	169,691	D		
Common Stock	11/09/2012	11/09/20	)12	S	2,000	D	\$ 48.422 (3)	167,691	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: BIENAIME JEAN JACQUES - Form 4

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	of Derivative Securities Acquired (A) or	Expiration D (Month/Day/ e	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owno Follo Repo
				Disposed						Trans
				of (D)						(Instr
				(Instr. 3,						
				4, and 5)						
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949	Х		Chief Executive Officer				
Signatures							
/s/ Laura Randall Woodhead, Attorney-in-Fact	11/09	9/2012					
**Signature of Reporting Person	D	ate					

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The price in Column 4 is a weighted average price. The prices actually received ranged from \$47.731 to \$47.736. The reporting person (1) will provide to the issue, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price in Column 4 is a weighted average price. The prices actually received ranged from \$47.001 to \$47.062. The reporting person (2) will provide to the issue, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price in Column 4 is a weighted average price. The prices actually received ranged from \$48.401 to \$48.45. The reporting person will (3) provide to the issue, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.

### Edgar Filing: BIENAIME JEAN JACQUES - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.